Drug Trial Radar · NCT06178991
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,795
Actual
Start
Dec 20, 2023
Primary completion
Nov 26, 2024
Study completion Nov 26, 2024
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Dec 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and caregivers in terms of simple and easy care. Around 8550 participants will be assigned into 1 of 8 vaccination groups (Group A, B, C, D, E, F, G or H) by chance. Cohort 1: Approximately 450 participants will be assigned by chance to one of the following: * Group A:Influenza and COVID-19 combination A vaccine, given at the same time in one arm and placebo (an injection consisting of just salt water and no medicines in it) in the opposite arm. * Group B: COVID-19 vaccine, given at the same time to one arm and licensed influenza vaccine in the opposite arm. Cohort 2: Approximately 4500 participants will be assigned by chance to one of the following: * Group C: Influenza and COVID-19 combination B vaccine, given at the same time in one arm and placebo in the opposite arm. * Group D: COVID-19 vaccine, given at the same time in one arm and licenced influenza vaccine in the opposite arm. Cohort 3: Approximately 3600 participants will be assigned by chance to one of the following: * Group E: Influenza and COVID-19 combination B vaccine. * Group F: COVID-19 vaccine. * Group G: Licenced influenza vaccine. * Group H: Investigational influenza vaccine. All participants in cohort 1 and cohort 2 will receive 2 injections and participants in cohort 3 will receive 1 injection as per their assigned study group at Visit 1. The participants will be followed for about 6 months. During this time, researchers will assess safety and the body's reaction to the vaccination over approximately 6 months. This will help understand if the study medicine is safe.
Conditions
- Influenza
- COVID-19
Interventions
Influenza and COVID-19 Combination ABiological
Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
Licensed influenza vaccineBiological
Licensed influenza vaccine
COVID-19 VaccineBiological
Pfizer-BioNTech COVID-19 vaccine
Influenza and COVID-19 Combination BBiological
Combined influenza and Pfizer-BioNTech COVID-19 vaccine
PlaceboBiological
Saline Solution
Investigational influenza vaccineBiological
Investigational influenza vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine ExtremityTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
- Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine ExtremityTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day1]
- Cohort 3: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine ExtremityTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
- Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following VaccinationTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
- Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following VaccinationTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
- Cohort 3: Percentage of Participants With Any Systemic Events for up to 7 Days Following VaccinationTime frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
- Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 4 Weeks After VaccinationTime frame: From Vaccination on Day 1 through 4 Weeks after Vaccination
- Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 4 Weeks After VaccinationTime frame: From Vaccination on Day 1 through 4 Weeks after Vaccination
- Cohort 3: Percentage of Participants Reporting AEs From Vaccination Through 4 Weeks After VaccinationTime frame: From Vaccination on Day 1 through 4 Weeks after Vaccination
- Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After VaccinationTime frame: From Vaccination on Day 1 through 6 Months after Vaccination
- Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After VaccinationTime frame: From Vaccination on Day 1 through 6 Months after Vaccination
- Cohort 3: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After VaccinationTime frame: From Vaccination on Day 1 through 6 Months after Vaccination
- Cohort 2: Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Strain-Specific Hemagglutination Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
- Cohort 2: Percentage of Participants and Difference in Percentage of Participants With Strain-Specific HAI Seroconversion at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
- Cohort 2: GMT and GMR of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Neutralizing Titers at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
- Cohort 2: Percentage of Participants and Difference in Percentage of Participants With SARS-CoV-2 Seroresponse at 4 Weeks After Vaccination: Non-inferiorityTime frame: At 4 Weeks after Vaccination
Locations
106 sites in 1 country. Site status is shown where the registry gives one.
North Alabama Research Center
Athens, Alabama
Accel Research Sites - Birmingham Clinical Research Unit
Birmingham, Alabama
AMR Clinical
Mobile, Alabama
HOPE Research Institute
Phoenix, Arizona
Foothills Research Center/ CCT Research
Phoenix, Arizona
Scottsdale Clinical Trials
Scottsdale, Arizona
Alliance for Multispecialty Research, LLC
Tempe, Arizona
Baptist Health Center For Clinical Research
Little Rock, Arkansas
Hope Clinical Research, Inc.
Canoga Park, California
Ascada Health PC dba Ascada Research
Fullerton, California
Orange County Research Center
Lake Forest, California
Ark Clinical Research
Long Beach, California
Collaborative Neuroscience Research, LLC
Los Alamitos, California
Artemis Institute for Clinical Research
San Diego, California
Acclaim Clinical Research
San Diego, California
Bayview Research Group, LLC
Valley Village, California
Synexus Clinical Research US, Inc.
Vista, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Tampa Bay Medical Research
Clearwater, Florida
Universal Axon Clinical Research, LLC
Doral, Florida
Proactive Clinical Research,LLC
Fort Lauderdale, Florida
Finlay Medical Research
Greenacres City, Florida
Indago Research & Health Center, Inc
Hialeah, Florida
Best Quality Research,Inc.
Hialeah, Florida
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida
Miami Clinical Research
Miami, Florida
Gerardo Polanco, MD
Miami, Florida
Research Institute of South Florida
Miami, Florida
Entrust Clinical Research
Miami, Florida
Miami Dade Medical Research Institute, LLC
Miami, Florida
Clinical Site Partners LLC, dba Flourish Research
Miami, Florida
Palm Springs Community Health Center
Miami Lakes, Florida
Angels Clinical Research Institute
Miami Lakes, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Innovation Medical Research Center
Palmetto Bay, Florida
DBC Research USA
Pembroke Pines, Florida
Angels Clinical Research Institute
Tampa, Florida
Centricity Research Columbus Georgia Multispecialty
Columbus, Georgia
AGILE Clinical Research Trials, LLC
Sandy Springs, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.